Therefore, a total of 25 manuscripts which presented data on the NAFLD/NASH diagnostic efficiency with CK-18, FGF-21, and combined biomarker panel (CBP) finally met the inclusion criteria and were included in this meta-analysis [11–35]. Here, FGF21 is linked to metabolic dysfunction-associated steatohepatitis.